Lantern Pharma (NASDAQ:LTRN – Get Free Report) is expected to be posting its Q3 2026 resultson Wednesday, November 11th. Analysts expect Lantern Pharma to post earnings of ($0.35) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:00 AM ET.
Lantern Pharma (NASDAQ:LTRN – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.19).
Lantern Pharma Trading Up 5.5%
NASDAQ LTRN opened at $0.60 on Tuesday. Lantern Pharma has a 12 month low of $0.50 and a 12 month high of $4.34. The stock has a market cap of $8.95 million, a P/E ratio of -0.37 and a beta of 2.48. The stock’s fifty day moving average price is $1.11 and its 200-day moving average price is $2.39.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on LTRN
Lantern Pharma Company Profile
Lantern Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company combines artificial intelligence, machine learning and genomic analysis to identify drug candidates, patient populations and biomarkers that may support more targeted oncology treatments.
Lantern Pharma’s technology platform, RADR, is designed to analyze large volumes of biological, genomic and clinical data to help accelerate drug discovery and development. The platform is used to evaluate existing and novel therapeutic compounds, identify potential mechanisms of action and support the development of biomarker-driven clinical programs.
The company’s oncology pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs such as LP-184 and LP-284.
Read More
- Five stocks we like better than Lantern Pharma
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
